The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Biotech Trends Update — Commercialization by Foundations: $500k to AVI BioPharma from DMD Organizations

Continuing a trend by nonprofits to invest directly in commercialization of relevant products, CureDuchenne and the Foundation to Eradicate Duchenne each awarded grants of $250,000 to AVI BioPharma, Inc. (NASDAQ: AVII) to support continued research and development of the Company’s drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD).

One interesting note here is the collaboration between foundations, something we also saw in an ALS project in December.   This is a great way for smaller foundations to maximize their impact on the (expensive!) drug development process.

Both foundations, run by parents of kids with DMD, are focused on commercial products:

“CureDuchenne is very happy to support AVI BioPharma as it advances these treatments to boys with DMD as soon as possible.”

“The exon-skipping strategies being developed by AVI offer the greatest prospect for meaningful clinical therapies.”

Bookmark and Share

About these ads

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 130 other followers